Drug intelligence / Profile preview

tangshenweining

Development stage: Unknown
Lead developer: Beijing Chaoyang Hospital
Administration: Oral

Overview

Tangshenweining is a Traditional Chinese Medicine (TCM) formula developed by Beijing Chaoyang Hospital, Capital Medical University, for the treatment of diabetic nephropathy. It is specifically formulated to address the TCM syndrome of Qi and Yin deficiency combined with blood stasis. The formula aims to improve renal function by enhancing vascular endothelial function and optimizing renal hemodynamics. Clinical research, including trial ChiCTR2300070218, focuses on its efficacy in reducing proteinuria and slowing the progression of kidney damage in diabetic patients by targeting microvascular complications.

Other names: Tangshenweining formulaTangshenweining granule

Targets

Sirtuin 1/Hypoxia-inducible factor 1-alpha signaling axisAMPK (Adenosine monophosphate–activated protein kinase)

Beyond the preview

Go deeper on tangshenweining.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tangshenweining.

Explore the full profile